Sachin Goel, MD
Cardiovascular Disease · Houston, TXNPI 1720255698
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (40.1%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Medtronic at 51.3% of the total. Reporting peaked in 2024 at $23,849 and has fallen 51.6% since, to $11,550 in 2025. Among cardiovascular disease clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 367 payments — averaging $230.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$43K
- Abbott$26K
- Boston Scientific$4K
- Siemens Medical Solutions USA, Inc.$4K
- W. L. Gore & Associates, Inc.$3K
- Edwards Lifesciences$3K
- plus $2K from 18 others
Across 89 payments — averaging $5263.15 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$397K
- Medtronic$30K
- Edwards Lifesciences$28K
- Bayer$13K
- Boston Scientific$364
What the payments were for
- Consulting fees$15,53318%
- Speaking & faculty fees$33,97340%
- Grants$930%
- Travel & lodging$14,83018%
- Food & beverage$20,21324%
- Education$260%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 179 | $43,445 |
| Abbott | 96 | $25,867 |
| Boston Scientific | 22 | $4,054 |
| Siemens Medical Solutions USA, Inc. | 5 | $3,517 |
| W. L. Gore & Associates, Inc. | 5 | $3,220 |
| Edwards Lifesciences | 22 | $2,508 |
| Jenavalve Technology, Inc. | 3 | $573 |
| Philips North America LLC | 6 | $559 |
| Amgen | 5 | $283 |
| Heartflow, Inc. | 1 | $113 |
| AstraZeneca | 2 | $108 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $76 |
| Ipsen Biopharmaceuticals, Inc | 2 | $55 |
| Biosense Webster, Inc. | 1 | $45 |
| Inari Medical, Inc. | 1 | $44 |
| Regeneron Healthcare Solutions, Inc. | 2 | $35 |
| Teleflex LLC | 2 | $32 |
| Cook Medical LLC | 2 | $27 |
| Boehringer Ingelheim | 1 | $23 |
| Baxter Healthcare | 1 | $23 |
| Bridgebio Pharma, Inc. | 1 | $18 |
| Johnson & Johnson | 1 | $15 |
| Scpharmaceuticals Inc. | 1 | $15 |
| Tactile Systems Technology Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COREVALVE EVOLUT R$28,072
- MitraClip$11,854
- NAVITOR$4,610
- Mitra Clip system$3,522
- Product in Development$3,143
- CoreValve Evolut$2,924
- GENERAL - STRUCTURAL HEART$1,164
- AMPLATZER Occluders$852
- Cardiovascular- Research only$807
- Tricuspid Valve Repair System$778
- Avalus$766
- Edwards SAPIEN 3 Transcatheter Heart Valve$565
- MitraClip System$384
- (9520) IGT Devices Undivided$263
- Repatha$234
- CARDIOMEMS$233
- APOLLOTM$226
- Micra$158
- HARMONY$155
- SAPIEN 3 Ultra RESILIA$151
How this compares
$84,668 in reported general payments places this provider in the 95th percentile of 1,515 cardiovascular disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 79 | $105,627 |
| FarxigaDapagliflozin Propanediol | 47 | $35,014 |
| JardianceEmpagliflozin | 42 | $31,160 |
| EntrestoSacubitril/Valsartan | 27 | $27,370 |
| Rosuvastatin Calcium | 75 | $1,874 |
| ClopidogrelClopidogrel Bisulfate | 92 | $1,301 |
| Metoprolol Succinate | 104 | $1,277 |
| Valsartan | 22 | $1,141 |
| Potassium Chloride | 17 | $1,056 |
| Losartan Potassium | 98 | $1,003 |
| Atorvastatin Calcium | 98 | $1,001 |
| Ezetimibe | 28 | $763 |
| Lisinopril | 50 | $747 |
| Nifedipine ErNifedipine | 11 | $461 |
| Amlodipine Besylate | 29 | $363 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $108 | $35,01447 claims |
| Boehringer IngelheimJardiance | $23 | $31,16042 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,515 cardiovascular disease providers in Texas.
Other cardiovascular disease in Houston
- Biykem BozkurtHouston$606K
- Reynolds DelgadoHouston$471K
- Christie BallantyneHouston$413K
- Asif AliHouston$411K
- Sanjay ManiarHouston$263K
- Joggy GeorgeHouston$231K
- Jerry EstepHouston$226K
- Stephen LittleHouston$144K
- Akira NishikawaHouston$109K
- Andres MesaHouston$103K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.